Comparison of assays measuring extracellular vesicle-tissue factor in plasma samples: Communication from the ISTH SSC Subcommittee on Vascular Biology

  • Amandine Bonifay
  • Nigel Mackman
  • Yohei Hisada
  • Ana Teresa Azevedo Sachetto
  • Chi Hau
  • Elaine Gray
  • John Hogwood
  • Anat Aharon
  • Lina Badimon
  • Lucio Barile
  • Justine Baudar
  • Lennart Beckmann
  • Birke Benedikter
  • Sara Bolis
  • Tarik Bouriche
  • Marta Brambilla
  • Jacopo Burrello
  • Marina Camera
  • Elena Campello
  • Camille Ettelaie
  • Dorothée Faille
  • Sophie Featherby
  • Corentin Franco
  • Maite Guldenpfennig
  • John-Bjarne Hansen
  • Coralie Judicone
  • Yohan Kim
  • Soren Risom Kristensen
  • Katrin Laakmann
  • Florian Langer
  • Nadezhda Latysheva
  • Fabrice Lucien
  • Erika Marques de Menezes
  • François Mullier
  • Philip Norris
  • Jette Nybo
  • Josune Orbe
  • Bjarne Osterud
  • Jose A Paramo
  • Claudia M Radu
  • Carmen Roncal
  • Nazanin Samadi
  • Omri Snir
  • Rosa Suades
  • Casper Wahlund
  • Corinne Chareyre
  • Evelyne Abdili
  • Kimberly Martinod
  • Johannes Thaler
  • Françoise Dignat-George
  • Rienk Nieuwland
  • Romaric Lacroix

Related Research units

Abstract

BACKGROUND: Scientific and clinical interest in extracellular vesicles (EVs) is growing. EVs that expose tissue factor (TF) bind factor VII/VIIa and can trigger coagulation. Highly procoagulant TF-exposing EVs are detectable in the circulation in various diseases, such as sepsis, COVID-19, or cancer. Many in-house and commercially available assays have been developed to measure EV-TF activity and antigen, but only a few studies have compared some of these assays.

OBJECTIVES: The International Society on Thrombosis and Haemostasis Scientific and Standardization Committee Subcommittee on Vascular Biology initiated a multicenter study to compare the sensitivity, specificity, and reproducibility of these assays.

METHODS: Platelet-depleted plasma samples were prepared from blood of healthy donors. The plasma samples were spiked either with EVs from human milk or EVs from TF-positive and TF-negative cell lines. Plasma was also prepared from whole human blood with or without lipopolysaccharide stimulation. Twenty-one laboratories measured EV-TF activity and antigen in the prepared samples using their own assays representing 18 functional and 9 antigenic assays.

RESULTS: There was a large variability in the absolute values for the different EV-TF activity and antigen assays. Activity assays had higher specificity and sensitivity compared with antigen assays. In addition, there was a large intra-assay and interassay variability. Functional assays that used a blocking anti-TF antibody or immunocapture were the most specific and sensitive. Activity assays that used immunocapture had a lower coefficient of variation compared with assays that isolated EVs by high-speed centrifugation.

CONCLUSION: Based on this multicenter study, we recommend measuring EV-TF using a functional assay in the presence of an anti-TF antibody.

Bibliographical data

Original languageEnglish
ISSN1538-7933
DOIs
Publication statusPublished - 10.2024

Comment Deanary

Copyright © 2024. Published by Elsevier Inc.

PubMed 38925490